Category: New products
-
Late Trial Testing Topical Gel for Diabetic Nerve Pain
26 June 2014. A late-stage clinical trial testing a topical gel to treat diabetic nerve pain completed its enrollment, according to BioDelivery Sciences International in Raleigh, North Carolina, the study’s sponsor. The trial is the first of two clinical studies of Clonidine Topical Gel in preparation for the company’s new drug application with the U.S.…
-
Epoxy/Carbon Ink 3-D Printed into Lightweight Cell Material
26 June 2014. Engineers at Harvard University developed an ink made of epoxy resins and carbon fibers, which when arrayed into a cellular pattern with three-dimensional printing, can produce a strong lightweight composite with the properties of balsa wood. Materials scientist and engineering professor Jennifer Lewis and postdoctoral researcher Brett Compton, now at Oak Ridge…
-
Paralyzed Man Moves Hand with Neuro-Signal Implant System
24 June 2014. Engineers at Battelle Memorial Institute and physicians at Ohio State University medical center in Columbus demonstrated a device that enables people with a spinal cord injury to direct movement of limbs with their thoughts. The research team’s first patient is Ian Burkhart, a 23 year-old man from Dublin, Ohio taking part in…
-
Ultrasound-Triggered Hydrogel Shown to Deliver Cancer Drug
24 June 2014. Bioengineers at Harvard University developed a technique with hydrogel and ultrasound that makes it possible to trigger short-term on-demand boosts of chemotherapy drugs. The team led by David Mooney of Harvard’s Wyss Institute for Biologically Inspired Engineering published its findings online today in the Proceedings of the National Academy of Sciences (paid…
-
Student Project Aims to Land Time Capsule on Mars
23 June 2014. Students from four U.S. universities — with help from research labs, not-for-profit organizations, and companies — are building a space vehicle to propel and land a time capsule of digital files from earth on the surface of Mars. The Time Capsule to Mars project also plans to raise $25 million through crowdfunding…
-
Foundation, Biopharm Partner on RNA-Interference Therapy
19 June 2014. Alnylam Pharmaceuticals Inc. in Cambridge, Massachusetts and the Alpha-1 Project in Miami are collaborating on advancing Alnylam’s therapy to treat alpha-1 antitrypsin deficiency, a rare genetic condition responsible for liver disorders and a lung disease similar to chronic obstructive pulmonary disease or COPD. Alpha-1 Project is the for-profit venture division of the…
-
Lasers Embed Sensors in Smartphone Display Glass
19 June 2014. Engineers at École Polytechnique de Montréal and Corning Inc. in Corning, New York designed a process for embedding sensors into the display glass covers on smartphones. The research team led by doctoral candidate Jerome Lapointe published its findings in the 30 June 2014 issue of the journal Optics Express, published by Optical…
-
Code Language Developed for Building Lab-On-Chip Devices
17 June 2014. Engineers at University of California in Riverside developed a programming language to automate the design of lab-on-a-chip devices used in medical diagnostics and other life science applications. The team from the lab of computer science and engineering professor Philip Brisk published its results in a recent issue of the ACM Journal on…
-
Spin-Off Company Develops Drill-Less Tooth Cavity Treatment
16 June 2014. A spin-off company from Kings College London in the U.K. is developing a technology that makes treating tooth cavities a painless electrical process. Reminova Ltd. — located in Perth, Scotland — was founded earlier this year and is led by two Kings College dental faculty, Nigel Pitts and Chris Longbottom, who serve…
-
FDA Grants Experimental Leukemia Drug Orphan Status
16 June 2014. Agios Pharmaceuticals Inc. in Cambridge, Massachusetts says the U.S. Food and Drug Administration designated its therapy for acute myelogenous leukemia an orphan drug, qualifying it for tax incentives and other benefits. The orphan drug status comes at the same time of new findings reported from an early clinical trial of the drug,…